On Nov 01, major Wall Street analysts update their ratings for $Blueprint Medicines (BPMC.US)$, with price targets ranging from $105 to $135.
Morgan Stanley analyst Michael Ulz maintains with a hold rating, and maintains the target price at $120.
Barclays analyst Peter Lawson maintains with a hold rating, and maintains the target price at $105.
Needham analyst Ami Fadia maintains with a buy rating, and adjusts the target price from $133 to $135.
JMP Securities analyst Reni Benjamin maintains with a buy rating, and maintains the target price at $125.
H.C. Wainwright analyst Andrew Fein maintains with a buy rating, and maintains the target price at $135.
Furthermore, according to the comprehensive report, the opinions of $Blueprint Medicines (BPMC.US)$'s main analysts recently are as follows:
The firm has adjusted its expectations slightly downwards for Blueprint Medicines, yet maintains a positive outlook on the stock. This optimism is based on the anticipation of a guidance for Ayvakit that surpasses consensus for FY25 and promising early data from the POS BLU-808 Phase 1 study expected in early 2025.
Here are the latest investment ratings and price targets for $Blueprint Medicines (BPMC.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月1日，多家华尔街大行更新了$Blueprint Medicines (BPMC.US)$的评级，目标价介于105美元至135美元。
摩根士丹利分析师Michael Ulz维持持有评级，维持目标价120美元。
巴克莱银行分析师Peter Lawson维持持有评级，维持目标价105美元。
Needham分析师Ami Fadia维持买入评级，并将目标价从133美元上调至135美元。
JMP Securities分析师Reni Benjamin维持买入评级，维持目标价125美元。
H.C. Wainwright分析师Andrew Fein维持买入评级，维持目标价135美元。
此外，综合报道，$Blueprint Medicines (BPMC.US)$近期主要分析师观点如下：
以下为今日5位分析师对$Blueprint Medicines (BPMC.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
